Roche Holdings, Inc. completed its acquisition of 89bio, Inc. on 2025-10-01, according to the Form 8-K 89bio, Inc. filed with the SEC on 2025-10-30. The filing's Item 2.01 states no aggregate dollar price. 89bio, Inc. filed the report because the deal made it part of Roche Holdings, Inc..
| Acquirer | Roche Holdings, Inc. |
|---|---|
| Acquired | 89bio, Inc. |
| Completed | 2025-10-01 |
| Reported by | 89bio, Inc. (ETNB), the company acquired |
| Filing | Form 8-K, filed 2025-10-30 |
Want the whole picture on Roche Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Roche Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Roche Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Upon completion of the Merger, the Company became a wholly owned subsidiary of Parent.
More from the filing
As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the " SEC ") by 89bio, Inc., a Delaware corporation (the " Company "), on September 18, 2025, the Company entered into an Agreement and Plan of Merger (the " Merger Agreement "), dated as of September 17, 2025, with Roche Holdings, Inc., a Delaware corporation (" Parent "), and Bluefin Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Merger Sub ").
Pursuant to the Merger Agreement, on October 1, 2025, Merger Sub commenced a tender offer to purchase all of the outstanding shares (the " Shares ") of common stock, par value $0.001 per share, of the Company, for (i) $14.50 per Share, in cash, without interest (the " Closing Amount ") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a " CVR ") per Share, representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share in cash, without interest less any required withholding taxes, upon the achievement of
The Offer and withdrawal rights expired as scheduled at one minute following 11:59 p.m., New York City Time, on October 29, 2025 (such date and time, the " Expiration Time ").
Quoted from 89bio, Inc.'s Form 8-K.
This is the only completed acquisition Roche Holdings, Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Roche Holdings, Inc.Look up Roche Holdings, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.